EVOKE PHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.458 USD | +5.05% |
|
-2.24% | -56.39% |
| 04-24 | Transcript : Evoke Pharma, Inc. - Special Call | |
| 03-21 | Evoke Pharma, Inc. Announces Board Changes as of March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 39.26 | 68.09 | 17.96 | 8.959 | 3.511 | 3.883 | - | - |
| Enterprise Value (EV) 1 | 39.26 | 68.09 | 17.96 | 8.959 | 3.511 | 3.883 | 3.883 | 3.883 |
| P/E ratio | -5.06 x | -4.96 x | -2.04 x | -1.02 x | -0.45 x | -1.99 x | 15.3 x | 2.18 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | 2,958 x | 11.1 x | 3.57 x | 0.68 x | 0.28 x | 0.18 x | 0.12 x |
| EV / Revenue | - | 2,958 x | 11.1 x | 3.57 x | 0.68 x | 0.28 x | 0.18 x | 0.12 x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 2,019 | 2,199 | 2,721 | 3,343 | 3,343 | 8,478 | - | - |
| Reference price 2 | 19.44 | 30.96 | 6.600 | 2.680 | 1.050 | 0.4580 | 0.4580 | 0.4580 |
| Announcement Date | 12/03/20 | 11/03/21 | 08/03/22 | 21/03/23 | 14/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 0.023 | 1.618 | 2.509 | 5.181 | 14.08 | 21.9 | 32.03 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -7.154 | -13.05 | -8.152 | -7.786 | -7.431 | -3.004 | 1.669 | 9.374 |
| Operating Margin | - | -56,678.32% | -503.79% | -310.37% | -143.44% | -21.33% | 7.62% | 29.27% |
| Earnings before Tax (EBT) 1 | -7.126 | -13.15 | -8.538 | -8.224 | -7.792 | -3.361 | 1.326 | 9.031 |
| Net income 1 | -7.126 | -13.15 | -8.538 | -8.224 | -7.792 | -3.361 | 0.995 | 6.773 |
| Net margin | - | -57,144.53% | -527.66% | -327.83% | -150.41% | -23.87% | 4.54% | 21.15% |
| EPS 2 | -3.840 | -6.240 | -3.240 | -2.620 | -2.330 | -0.2300 | 0.0300 | 0.2100 |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 12/03/20 | 11/03/21 | 08/03/22 | 21/03/23 | 14/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.9304 | 0.3606 | 0.4184 | 0.4618 | 0.8321 | 0.7964 | 0.8104 | 1.131 | 1.563 | 1.676 | 2.138 | 2.98 | 4.104 | 4.859 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -1.845 | -1.547 | -2.051 | -2.113 | -1.913 | -1.71 | -2.155 | -1.784 | -1.603 | -1.888 | -1.695 | -1.127 | -0.381 | 0.199 |
| Operating Margin | -198.28% | -429.14% | -490.26% | -457.48% | -229.85% | -214.7% | -265.93% | -157.72% | -102.6% | -112.65% | -79.28% | -37.82% | -9.28% | 4.1% |
| Earnings before Tax (EBT) 1 | -1.969 | -1.672 | -2.174 | -2.233 | -2.014 | -1.803 | -2.243 | -1.868 | -1.694 | -1.987 | -1.784 | -1.217 | -0.47 | 0.11 |
| Net income 1 | -1.969 | -1.672 | -2.174 | -2.233 | -2.014 | -1.803 | -2.243 | -1.868 | -1.694 | -1.987 | -1.784 | -1.217 | -0.47 | 0.11 |
| Net margin | -211.67% | -463.81% | -519.54% | -483.62% | -242.02% | -226.43% | -276.78% | -165.1% | -108.39% | -118.58% | -83.44% | -40.84% | -11.45% | 2.26% |
| EPS 2 | -0.7200 | -0.7200 | -0.8400 | -0.7100 | -0.6000 | -0.5300 | -0.6700 | -0.5600 | -0.5100 | -0.5900 | -0.2100 | -0.1400 | -0.0200 | 0.0100 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 10/11/21 | 08/03/22 | 10/05/22 | 10/08/22 | 09/11/22 | 21/03/23 | 15/05/23 | 10/08/23 | 09/11/23 | 14/03/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - | - |
| Announcement Date | 12/03/20 | 11/03/21 | 08/03/22 | 21/03/23 | 14/03/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.458
USD
Average target price
7
USD
Spread / Average Target
+1,428.38%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -56.39% | 3.88M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- EVOK Stock
- Financials Evoke Pharma, Inc.
